Cravens & CO Advisors, LLC Bristol Myers Squibb CO Transaction History
Cravens & CO Advisors, LLC
- $129 Billion
- Q1 2025
A detailed history of Cravens & CO Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Cravens & CO Advisors, LLC holds 5,304 shares of BMY stock, worth $243,877. This represents 0.25% of its overall portfolio holdings.
Number of Shares
5,304
Previous 5,286
0.34%
Holding current value
$243,877
Previous $299 Million
8.2%
% of portfolio
0.25%
Previous 0.23%
Shares
4 transactions
Others Institutions Holding BMY
# of Institutions
2,730Shares Held
1.59BCall Options Held
26MPut Options Held
24.2M-
Vanguard Group Inc Valley Forge, PA191MShares$8.8 Billion0.22% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.3 Billion0.15% of portfolio
-
Jpmorgan Chase & CO New York, NY108MShares$4.97 Billion0.52% of portfolio
-
State Street Corp Boston, MA94.8MShares$4.36 Billion0.24% of portfolio
-
Capital International Investors Los Angeles, CA66.5MShares$3.06 Billion0.83% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $97.8B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...